Skip to main content

Abstract

The clinical implications of pharmacogenetics are vast and many more are becoming apparent as research continues. Health-care providers will increasingly need to take pharmacogenetics into consideration when prescribing medications. Each patient’s history, physical condition, gender, and ethnicity must be considered when prescribing drugs. Specific genotypic testing of patients for polymorphisms that influence drug metabolism and action will become a clinical reality. Silicone chip technology utilizing single-nucleotide polymorphisms will be able to provide a practitioner with reliable and timely information in an office setting to guide practice. Genetics and pharmacology are no longer separate sciences.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 269.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 349.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Selected References

  • Carson PE, Flanagan CL, Ickes CE, Alvong AS. Enzymatic deficiency in primaquine sensitive erythrocytes. Science 1956;124:484, 485.

    Article  PubMed  Google Scholar 

  • Committee on Quality of Health Care in America: Institute of Medicine. To Err is Human: Building A Safer Health System. Washington, DC: National Academy Press, 2000.

    Google Scholar 

  • Evans DA. Genetic variations in the acetylation of isoniazid and other drugs. Ann N Y Acad Sci 1968;151(2):723–733.

    Article  PubMed  CAS  Google Scholar 

  • Flockhart DA. Drug Interactions: Defining genetic influences on pharma-cologic responses. Indiana University School of Medicine, Division of Clinical Pharmacology. Indianapolis, Indiana. http://www.drug-interactions.com. Retrieved January 20, 2004.

  • Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safety of newly approved medicines: Do recent market removals mean there is a problem? JAMA 1999;281(18): 1728–1734.

    Article  PubMed  CAS  Google Scholar 

  • Garrod AE, Harris H. Garrod’s Inborn Errors of Metabolism. London, New York: Oxford University Press, 1963.

    Google Scholar 

  • Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000;109(2):87–94.

    Article  Google Scholar 

  • Guthrie R. Screening for “inborn errors of metabolism” in the newborn infant-a multiple test program. Birth Defects 1968;4:92–98.

    Google Scholar 

  • Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001;250(3): 186–200.

    Article  PubMed  CAS  Google Scholar 

  • Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999;20(8):342–349.

    Article  PubMed  CAS  Google Scholar 

  • Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycopro-tein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101(2):289–294.

    Article  PubMed  CAS  Google Scholar 

  • Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med, 1998; 338(2): 86–93.

    Article  PubMed  CAS  Google Scholar 

  • Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998;279(15):1200–1205.

    Article  PubMed  CAS  Google Scholar 

  • Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet 1999;56(4):247–258.

    Article  PubMed  CAS  Google Scholar 

  • Smith RL. The paton prize award. The discovery of the debrisoquine hydroxylation polymorphism: scientific and clinical impact and consequences. Toxicology 2001;168(1):11–19.

    PubMed  CAS  Google Scholar 

  • Trenter M. From test tube to patient: improving health through human drugs. Washington, D C: U.S. Food and Drug Administration Center for Drug Evaluation and Research, 1999 pp. 1–100.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc.

About this chapter

Cite this chapter

Edkins, R.E., Cheek, D.J. (2006). Pharmacogenetics. In: Runge, M.S., Patterson, C. (eds) Principles of Molecular Medicine. Humana Press. https://doi.org/10.1007/978-1-59259-963-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-963-9_5

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-202-5

  • Online ISBN: 978-1-59259-963-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics